Newman Dignan & Sheerar Inc. lowered its position in shares of Merck & Company, Inc. (NYSE:MRK) by 0.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,701 shares of the company’s stock after selling 606 shares during the quarter. Merck & comprises 2.3% of Newman Dignan & Sheerar Inc.’s portfolio, making the stock its 9th largest position. Newman Dignan & Sheerar Inc.’s holdings in Merck & were worth $4,083,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Atwood & Palmer Inc. raised its stake in Merck & by 12.8% during the second quarter. Atwood & Palmer Inc. now owns 6,624 shares of the company’s stock valued at $425,000 after buying an additional 750 shares in the last quarter. NBT Bank N A NY raised its stake in Merck & by 0.8% during the second quarter. NBT Bank N A NY now owns 78,782 shares of the company’s stock valued at $5,049,000 after buying an additional 615 shares in the last quarter. Cornerstone Advisory LLP raised its stake in Merck & by 0.4% during the second quarter. Cornerstone Advisory LLP now owns 11,110 shares of the company’s stock valued at $712,000 after buying an additional 43 shares in the last quarter. Good Life Advisors LLC raised its stake in Merck & by 7.6% during the second quarter. Good Life Advisors LLC now owns 5,879 shares of the company’s stock valued at $371,000 after buying an additional 414 shares in the last quarter. Finally, Crawford Investment Counsel Inc. raised its stake in Merck & by 1.1% during the second quarter. Crawford Investment Counsel Inc. now owns 1,302,852 shares of the company’s stock valued at $83,500,000 after buying an additional 14,096 shares in the last quarter. Hedge funds and other institutional investors own 72.98% of the company’s stock.

In related news, Director Thomas H. Glocer sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $56.20, for a total value of $281,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.25% of the company’s stock.

MRK has been the topic of several research reports. Jefferies Group LLC restated a “sell” rating and set a $52.00 price objective on shares of Merck & in a research note on Sunday, August 20th. BMO Capital Markets restated a “buy” rating and set a $72.00 price objective on shares of Merck & in a research note on Friday, September 8th. Credit Suisse Group cut their price objective on Merck & from $75.00 to $74.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 30th. SunTrust Banks, Inc. lowered Merck & from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Zacks Investment Research lowered Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $66.44.

Merck & Company, Inc. (NYSE MRK) traded down $0.02 during trading hours on Friday, hitting $54.35. The stock had a trading volume of 4,341,296 shares, compared to its average volume of 14,632,603. The company has a market capitalization of $148,127.64, a price-to-earnings ratio of 13.98, a PEG ratio of 2.34 and a beta of 0.78. Merck & Company, Inc. has a 52 week low of $53.63 and a 52 week high of $66.80. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16.

Merck & (NYSE:MRK) last posted its earnings results on Friday, October 27th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.08. The company had revenue of $10.33 billion during the quarter, compared to analyst estimates of $10.54 billion. Merck & had a return on equity of 27.08% and a net margin of 11.60%. The business’s revenue was down 2.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.07 earnings per share. sell-side analysts forecast that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Merck & Company, Inc. (MRK) Holdings Cut by Newman Dignan & Sheerar Inc.” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/merck-company-inc-mrk-holdings-cut-by-newman-dignan-sheerar-inc/1725929.html.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.